Lack of Effect of Cholestyramine on the Pharmacokinetics of Clofibrate in Man
- 1 February 1975
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 5 (1), 177-185
- https://doi.org/10.1111/j.1365-2362.1975.tb00444.x
Abstract
The study was undertaken to determine whether cholestyramine (16 g daily) interfered with clofibrate absorption when the two drugs were given together. Fifteen patients taking 1 g of clofibrate twice daily (for 2 to 416 weeks) participated in the study. Clofibrate (as the acid, p-chlorophenoxyisobutyric acid, CPIB) was quantified by thin-layer and gas-liquid chromatography. In patients taking clofibrate only, mean plasma CPIB concentration before the morning dose of clofibrate was 123 mug/ml. Peak levels were reached 3.5 hours after drug intake, the mean peak plasma CPIB concentration being 193 mug/ml. Absorption of CPIB exceeded 99%. Ninety-eight percent of the daily CPIB-intake was excreted in the urine, 61% being conjugated. In vivo degradation of CPIB did not occur. Free and conjugated CPIB was present in bile (mean fasting level being 55 mug/ml. The decay of radioactive CPIB in plasma was not log-linear: the mean t 1/2 of the first exponential was 0.45 hours, and of the second 15.1 hours. The pool size in 3 patients 3 hours after the morning dose of clofibrate was 1054 mg. CPIB was not detectable in adipose tissue, and kinetic data gave no hint of drug accumulation in patients on long-term therapy. In 6 patients given cholestyramine together with clofibrate, there was no significant alteration in fasting plasma CPIB levels, 24-hour urinary and faecal excretion of CPIB or in the half-life and pool size of the drug. A short delay in reaching peak plasma CPIB levels was the only consistent finding.Keywords
This publication has 24 references indexed in Scilit:
- Mechanism of the Hypolipemic Effect of Clofibrate in Postabsorptive ManJCI Insight, 1973
- Interruption of the enterohepatic circulation of digitoxin by cholestyramineJCI Insight, 1971
- Combined Use of Clofibrate and Cholestyramine or DEAE Sephadex in HypercholesterolaemiaBMJ, 1971
- Long-Term Effects of Clofibrate (Atromid-S) on Serum Lipids in ManCirculation, 1969
- Reduction of serum triglycerides and cholesterol by ethyl p-chlorophenoxyisobutyrate (CPIB)The American Journal of Cardiology, 1965
- Serial Studies on the Metabolism of Human Adipose Tissue. I. Lipogenesis and Free Fatty Acid Uptake and Release in Small Aspirated Samples of Subcutaneous Fat *JCI Insight, 1964
- EXPERIMENTAL EVALUATION OF AN ORALLY ACTIVE COMBINATION OF ANDROSTERONE WITH ETHYL CHLOROPHENOXYISOBUTYRATEThe Lancet, 1962
- Modification of Metabolism and Distribution of Lipids by Ethyl ChlorophenoxyisobutyrateNature, 1962
- The mechanism of glucuronide formationBiochemical Pharmacology, 1961
- Synthesis of glucuronides and of uridine diphosphate glucuronic acid in kidney cortex and gastric mucosaBiochimica et Biophysica Acta, 1959